The story has been revised to reflect changes made by Life Technologies to its third-quarter revenue and EPS figures as a result of a $48.6 million verdict against the company.

NEW YORK (GenomeWeb News) – Life Technologies reported after the close of the market on Thursday that its third-quarter revenues slid 2 percent year over year, though it beat consensus Wall Street estimates on the top and bottom line.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.